Refine
Has Fulltext
- yes (27)
Is part of the Bibliography
- yes (27)
Year of publication
Document Type
- Journal article (27)
Language
- English (27) (remove)
Keywords
- adrenocortical carcinoma (5)
- CYP2W1 (2)
- Cushing’s syndrome (2)
- FGFR (2)
- SOAT1 (2)
- adrenal tumours (2)
- immunotherapy (2)
- machine learning (2)
- metabolomics (2)
- prognosis (2)
- 18F-FDG (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- ACTH (1)
- Adrenocortical Carcinoma (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CXCR4 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cushing syndrome (1)
- Cushing's disease (1)
- Cushing’s disease (1)
- EMT (1)
- FGF-pathway (1)
- Mitotane (1)
- NCI-H295R (1)
- NR3C1 (1)
- PD-L1 (1)
- PET (1)
- Positronen-Emissions-Tomografie (1)
- Primary hyperparathyroidism (pHPT) (1)
- RNA Expression (1)
- RNAScope (1)
- SNP (1)
- TKI (1)
- USP8 (1)
- [18F]FDG-PET-CT (1)
- abdominal lymph node metastases (1)
- adjuvant platinum-based chemotherapy (1)
- adrenal (1)
- adrenal gland (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- amphiphilic block copolymer (1)
- autonomous cortisol secretion (1)
- biomarker (1)
- biomarkers (1)
- cancer (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- catecholamines (1)
- chemokine receptor (1)
- cholesterol metabolism (1)
- combination (1)
- confounders (1)
- dexamethasone suppression test (1)
- diagnosis (1)
- diagnostics (1)
- drug therapy (1)
- ectopic (1)
- endogenous hypercortisolism (1)
- epithelial markers (1)
- feature selection (1)
- glucocorticoid excess (1)
- high dose dexamethasone suppression test (1)
- hormones (1)
- hypercortisolism (1)
- hypertension (1)
- imaging (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immune response (1)
- immunity (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- liver resection (1)
- lymphocytes (1)
- mass spectronomy (1)
- medullary thyroid cancer (1)
- medullary thyroid carcinoma (1)
- mesenchymal markers (1)
- mitotane (1)
- molecular diagnostics (1)
- morbidity (1)
- mortality (1)
- multi-tyrosine kinase inhibitor (1)
- multicenter (1)
- mutation triggers (1)
- normal adrenal glands (1)
- papillary thyroid carcinoma (PTC) (1)
- paraganglioma (1)
- parathyroid carcinoma (1)
- patient survival (1)
- pembrolizumab (1)
- personalized medicine (1)
- pheochromocytoma (1)
- pheochromocytoma/paraganglioma (1)
- phosphorylation (1)
- plasma NMR (1)
- poly(2-oxazoline) (1)
- positron emission tomography (1)
- preanalytical conditions (1)
- predictive marker (1)
- preoperative localization (1)
- primary aldosteronism (1)
- prognostic factors (1)
- prostate cancer (1)
- radical resection (1)
- radioiodine (1)
- radiotherapy (RT) (1)
- rearranged during transfection (1)
- recurrence-free survival (1)
- repeat surgery (1)
- repeated surgery (1)
- retrospective study (1)
- selpercatinib (1)
- solubility enhancement (1)
- surgical oncology (1)
- survival (1)
- survival analysis (1)
- t-lymphocytes (1)
- target therapies (1)
- targeted metabolomics (1)
- thyroid carcinoma (TC) (1)
- treatment outcome (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase inhibitor (TKI) (1)
- unsupervised clustering (1)
- vandetanib (1)
- variant (1)
Institute
- Medizinische Klinik und Poliklinik I (24)
- Pathologisches Institut (7)
- Comprehensive Cancer Center Mainfranken (6)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (4)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (3)
- Institut für Funktionsmaterialien und Biofabrikation (2)
- Urologische Klinik und Poliklinik (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Institut für Klinische Biochemie und Pathobiochemie (1)
Sonstige beteiligte Institutionen
Background
International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low.
Methods
We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. Primary endpoint: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses.
Results
In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50–60 Gy (n = 20) or 20–49 Gy (n = 69), stereotactic body RT of 35–50 Gy (SBRT) (n = 36), or brachytherapy of 12–25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0–148.6). In comparison to cRT\(_{20-49Gy}\), tTTP was significantly longer for cRT\(_{50-60Gy}\) (multivariate adjusted HR 0.10; 95% CI 0.03–0.33; p < 0.001) and SBRT (HR 0.31; 95% CI 0.12–0.80; p = 0.016), but not for BT (HR 0.66; 95% CI 0.22–1.99; p = 0.46). Toxicity was generally mild and moderate with three grade 3 events. No convincing predictive factors could be established.
Conclusions
This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.